Kornimate/medical-research-clean huggingface dataset:
pravastatin reduces acute phase response of zoledronic acid

Conditions: Postmenopausal Osteoporosis

Summary: acute phase response (apr) is one of the most common adverse events in osteoporosis with zoledronic acid treatment. it's reported that this reaction is related to the blockade of the mevalonate pathway, leading to isopentenyl pyrophosphate (ipp) accumulation. and the latter can active γδt cells in the circulation, resulting in inflammatory cytokine release. statins can inhibit the conversion of hmg-coa to mevalonate that may reduce the accumulation of ipp. therefore, it is possible that statins can be taken in advance to reduce apr caused by zoledronic acid infusion.


Eligibility criteria:
inclusion criteria: 1. chinese han ethnic postmenopausal women. 2. bone mineral density values of less than 2.5 standard deviations (sd) below the normal adult mean. 3. willing to participate in this study. exclusion criteria: 1. prior treatment with biphosphonates (oral or intravenous). 2. fever and/or any viral or bacterial infections within 30 days prior to randomization. 3. patients with evidence of any cancer or with a history of cancer. 4. contraindication to zoledronic acid: known hypersensitivity to zoledronic acid or other bisphosphonate or zoledronic acid formulation (excipients); serum calcium level \< 2.13 mmol/l (8.5 mg/dl), free serum calcium level \<0.95 mmol/l (3.8 mg/dl) or untreated hypocalcemia; childbearing or child-breastfeeding women; creatinine clearance \< 35 ml/min; restrictions: patients currently receiving aminoglycoside, diuretics or thalidomide. 5. contraindication to pravastatin: known hypersensitivity to pravastatin or other excipients in pravastatin sodium formulation. restrictions: patients with severe liver insufficiency, history of severe liver insufficiency, active liver disease or continuously elevated transaminase; patients with severe renal insufficiency or history of severe renal insufficiency; patients currently receiving fibrates (e.g., bezafibrate), immunosuppressive drug (e.g., cyclosporine) or niacin. 6. any physiological or medical condition which, in the opinion of the investigator, would preclude the participant from this trail.

Keywords: acute phase response zoledronic acid pravastatin
functional recovery in critically ill children, the wee-cover multicentre study

Conditions: Pediatric Critical Illness

Summary: when children suffer from a critical-illness, the investigators focus on resuscitating and saving lives. once these children leave the pediatric intensive care unit, very little is known about what happens to them - how long it takes for them to recover, how families cope, and what factors that impede their recovery. the specific objective of this research project is to evaluate how children and their families recover after a critical illness. research hypotheses: following a critical illness in children, 1) the rate and degree of health and functional recovery is influenced by the following factors: age, pre-admission co-morbid status, critical illness severity, discharge functional status, and time to initiating acute rehabilitation; 2) functional recovery is influenced by caregiver burden and health-related quality-of-life (hrqol).

the specific objective of this study is to evaluate the trajectory of health and functional outcomes in children following a critical illness, define poor functional recovery, and evaluate predictors of poor recovery. the research questions for this study are: 1) what are the health and functional outcomes in children affected by a critical illness, at 3 and 6 months following pediatric intensive care unit (picu) discharge? 2) what defines poor functional recovery? 3) what are predictors of poor functional recovery in critically ill children? 4) what are the most important and relevant outcomes in critically ill children, from the patient and caregiver's point of view? study design: prospective observational mixed methods longitudinal cohort study study setting: two academic pediatric centres in canada - mcmaster children's hospital and london health sciences centre.

Eligibility criteria:
inclusion criteria: * age over 12 months to 17 years * admitted to picu for at least 48 hours * ≥ one organ dysfunction on admission * informed consent of patient/substitute decision maker, and patient assent were appropriate exclusion criteria: * patients transferred directly from a neonatal intensive care unit prior to discharge home * patients who are already mobilizing well, or are at baseline functional status at time of screening * previous enrolment into this study * language barrier (i.e. no access to translation services)

Keywords: pediatrics, critical illness, recovery, function, health
vitoria sleep smart city: interactive intervention for sleep improvement

Conditions: Sleep Deprivation; Sleep Hygiene

Summary: currently, the investigators know that there is a high and increasing prevalence of sleep quality and quantity deficits in the general population with the social and health consequences that this entails. there are numerous activity wristbands linked to mobile apps that analyze sleep, but none can generate individualized recommendations for improvement interacting with the person. the main objective of the current project is to develop a virtual and interactive sleep assistant to increase the quantity and quality of sleep. secondary objectives being the improvement of daytime sleepiness and the quality of life of the persons. methodology: 202 participants in active employment who meet the criteria of "poor sleepers" (defined by a pittsburg test score \>5) are divided into 2 study groups. 1. intervention group: sleep data will be collected using validated questionnaires (sated and the sleep hygiene index) and objectively employing an activity bracelet, in which weekly, through a live chat, the medical staff of the sleep units will offer recommendations for the improvement of the deficits detected. 2. control group: same protocol as the intervention group, but the participants will not receive the recommendations via the interactive chat.


Eligibility criteria:
inclusion criteria: * patients aged 18 to 65 years exclusion criteria: * patients previously diagnosed and treated for sleep pathology (such as insomnia, obstructive sleep apnea (osa), restless legs syndrome (rls), narcolepsy or parasomnia, among others). * severe medical or psychiatric comorbidities. * subjects who are not capable of using mobile technology such as smartphone. * subjects who are not committed to actively participate, putting into practice the sleep recommendations given by the assistant.
early versus late laparoscopic exploration of common bile duct after failure of extraction of common bile duct stones by ercp

Conditions: Common Bile Duct Calculi

Summary: the goal of this work is to assess the best time to perform lc combined with lcbd exploration and the feasibility and safety of such procedure in patients with combined gbs and cbds after failure of ercp extraction of cbd stones .


Eligibility criteria:
inclusion criteria: 1. all patients that presented with calcular obstructive jaundice 2ry to cbd stones. 2. failed of extraction of common bile duct stone by ercp. exclusion criteria: 1. patients presented by cholangitis. 2. patients presented by acute pancreatitis. 3. patients that developed post ercp pancreatitis ,bleeding , perforation. 4. history of previous biliary surgery rather than cholecystectomy. 5. history of major upper abdominal surgery. 6. pregnant females. 7. patients with liverchirosis, abdominal malignancy , and those unfit for surgery.
prevention of post-operative nausea and vomiting with propofol infusion

Conditions: Post-operative Nausea and Vomiting

Summary: the purpose of this study is to clarify whether or not a low-dose propofol infusion can effectively prevent postoperative nausea and vomiting (ponv) in patients who have a documented history of ponv and/or motion sickness.

propofol is administered as both low dose and as sole anesthetic in patients with history of ponv and/or motion sickness. but efficacy of one dose over the other is not studied. this study plans to clarify if propofol in low dose is as effective as its administration as sole anesthetic in patients with history of ponv and/or motion sickness

Eligibility criteria:
inclusion criteria: 1. undergoing general anesthesia for elective surgery 2. documented history of patient's self-disclosure of ponv and/or motion sickness during pre-anesthesia discussions 3. no documented allergy/adverse reaction to propofol 4. english speaking 5. at least 18 years of age exclusion criteria: 1. any anti-nausea medication taken within 24 hours prior to surgery 2. unable to provide consent independently 3. allergy or adverse reaction to propofol 4. emergency surgery

Keywords: post-operative nausea post-operative vomiting propofol motion sickness
light therapy in the treatment of leg pain

Conditions: Tibial Fractures; Leg Injuries

Summary: the purpose of this study is to apply anodyne therapy to active duty soldiers, who have shin splints, to evaluate healing time and effectiveness.

tibial stress reactions and fractures are often difficult to treat, and therefore, many soldiers proceed to a medical disability/discharge. it is felt that with the use of the mire technology, active duty soldiers with tibial stress reactions and fractures will heal more quickly and completely. all soldiers will have a documented bone scintigraph as evidence for tibial stress reaction or fracture prior to enrollment. in addition, pain-pressure goniometric measures and time to complete the balke protocol will also be used to assess healing with the mire technology. comparison: soldiers with active mire technology, compared to soldiers with placebo mire technology.

Eligibility criteria:
inclusion criteria: * active duty soldier * exertional leg pain of greater than 3 months duration * documented bone scintigraphic evidence for tibial stress reaction or fracture exclusion criteria: * known leg pathology other than stress reaction or fracture * service members known to be leaving area within next 6 months * pregnant females * high risk cardiopulmonary patients * patients with assisted walking devices * patients with two or more cardiac risk factors

Keywords: pain, intractable infrared rays leg
computerized cognitive training for childhood cancer survivors

Conditions: Primary Brain Tumor

Summary: specific aim 1: to assess the feasibility and acceptability of a home-based, computerized attention training program with survivors of central nervous system (cns) impacting pediatric cancer (e.g. acute lymphocyte leukemia \[all\], brain tumors). specific aim 2: to estimate the effect size of this attention training program with survivors of childhood cancer to determine whether a larger-scale clinical trial is warranted.

pediatric patients meeting initial eligibility criteria will be identified through the databases for each clinic (n = approximately 50 survivors in each clinic). a letter explaining the purpose of the study will then be sent to the parents of these patients. interested parents will be invited to contact study personnel by phone or email for a thorough review of the study and to schedule a screening appointment. after obtaining written informed consent and assent (from parents and child, respectively), screening procedures will include administration of an abbreviated intellectual test battery, two working memory tasks, and a computerized attention measure to the survivor. parents will complete questionnaire measures regarding their child's adaptive, behavioral, emotional, and attentional functioning; follow-up interviewing will be conducted to clarify any potential problems identified on the questionnaires. the entire screening procedure is estimated to take approximately 60 minutes for the survivor and 30-45 minutes for parents. to maximize efficiency, a research assistant will complete testing with the child and a psychologist will explain the questionnaire measures to the parent and conduct any follow-up interviewing.

Eligibility criteria:
inclusion criteria: 1. a t-score greater than the 75th percentile on either the cognitive problems/inattention or the dsm-iv inattention subscales of the conners' parent rating scale 2. one or more standard deviations below the mean on the working memory index of the wisc-iv or a working memory index that is one or more standard deviations below the participant's estimated iq. these criteria are based on the eligibility criteria used in the largest trial to date of psychostimulant methylphenidate (mph; commonly known as ritalin) with survivors of childhood cancer. exclusion criteria: 1. estimated iq ≤ 70 2. motor, visual, or auditory handicap that prevents computer use 3. a diagnosis of attention-deficit hyperactivity disorder (adhd), oppositional defiant disorder (odd), depression, autism, or pervasive developmental disorder (pdd) 4. insufficient fluency in english. participants who are currently taking stimulant medications (stable dose for at least 30 days) for attentional difficulties, but who meet inclusion criteria will be allowed to participate.

Keywords: pediatric brain tumor survivors
the immediate effect of mulligan's mobilization with movement on shoulder girdle' pain, range of motion and muscle activity, in subjects with shoulder impingement syndrome

Conditions: Shoulder Impingement Syndrome

Summary: the aim of present study was to evaluate the immediate effect of mulligan's mobilization with movement on shoulder girdle' pain, range of motion (rom) and muscle activity, in subjects with shoulder impingement syndrome

a randomized, single-blind, placebo-controlled clinical trial was conducted with a sample composed by twenty-four volunteers with sis, divided in mulligan's mwm and placebo groups. pain intensity in neer impingement signal and hawkins-kennedy impingement test, pressure pain threshold (ppt) on the lateral aspect of shoulder, rom of shoulder scaption until onset of pain, as well as the activity of trapezius (upper, middle and lower fibers) and serratus anterior muscles during this movement, were evaluated before and immediate (post-) intervention. the mulligan's mwm group received a mobilization with movement technique in the glenohumeral joint (sustained posterolateral glide during shoulder scaption), while no effective intervention was performed in the placebo group.

Eligibility criteria:
inclusion criteria: participants had superolateral shoulder pain and two out of four specified objective signs and symptoms: * positive neer test; * positive hawkins-kennedy test; * painful limitation of active arm elevation (flexion, abduction, scaption); * pain or limitation with functional movement patterns of hand behind back or hand behind head. exclusion criteria: * physician diagnosis of adhesive capsulitis; * grade iii rotator cuff tear; * calcific tendinosis confirmed by radiology; * systemic or neurological disorder; * cervical radiculopathy; a history of shoulder surgery; * corticosteroid injection within the past month; * subjects who had received physical therapy intervention for their shoulder within the past three months.

Keywords: subacromial impingement syndrome mobilization with movement pressure pain threshold surface electromyography
effect of eslicarbazepine acetate on the pharmacokinetics of metformin in healthy volunteers

Conditions: Neuropathic Pain

Summary: the primary objective was to investigate whether multiple-dose administration of eslicarbazepine acetate affects the pharmacokinetics of metformin.


Eligibility criteria:
inclusion criteria: * male or female subjects aged between 18 and 45 years, inclusive. * body mass index (bmi) between 19 and 30 kg/m2, inclusive. * healthy as determined by pre-study medical history, physical examination, vital signs, complete neurological examination and 12-lead ecg. * negative tests for hbsag, anti-hcvab and hiv-1 and hiv-2 ab at screening * clinical laboratory test results clinically acceptable at screening and admission to each treatment period. * negative screen for alcohol and drugs of abuse at screening and admission to each treatment period. * non-smokers or who smoke ≤ 10 cigarettes or equivalent per day. * able and willing to give written informed consent. * (if female) not of childbearing potential by reason of surgery or, if of childbearing potential, she used one of the following methods of contraception: double barrier or intrauterine device. * (if female) negative urine pregnancy test at screening and admission to each treatment period. exclusion criteria: * clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, haematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine, connective tissue diseases or disorders. * clinically relevant surgical history. * history of relevant atopy or drug hypersensitivity. * history of alcoholism or drug abuse. * consumed more than 14 units of alcohol a week. * significant infection or known inflammatory process at screening or admission to each treatment period. * acute gastrointestinal symptoms (e.g., nausea, vomiting, diarrhoea, heartburn) at the time of screening or admission to each treatment period. * used medicines within 2 weeks of admission to first period that may affect the safety or other study assessments, in the investigator's opinion. * used any investigational drug or participated in any clinical trial within 6 months prior to screening. * participated in more than 2 clinical trials within the 12 months prior to screening. * donated or received any blood or blood products within the 3 months prior to screening. * vegetarians, vegans or with medical dietary restrictions. * could not communicate reliably with the investigator. * unlikely to co-operate with the requirements of the study. * unwilling or unable to give written informed consent. * (if female) pregnant or breast-feeding. * (if female) of childbearing potential and she did not use an approved effective contraceptive method (double-barrier or intra-uterine device) or she used oral contraceptives.

Keywords: eslicarbazepine acetate zebinix metformin
clinical features and outcomes of cbp versus non-cbp in septic children

Conditions: Sepsis; Children, Only

Summary: the effect of continuous blood purification (cbp) in children is unclear. also, the timing of early application is still being explored. in this study, we need to explore the efficacy and the timing of application of cbp in children with sepsis or septic shock.

early intervention of cbp can remove inflammatory factors in patients with sepsis and reduce the damage of inflammatory factors to organs; at the same time, it can also promote the body's immune response, significantly improve immune dysfunction, and restore the body's immune balance. however, the timing of early application of cbp in childhood sepsis is still unclear. therefore, it is necessary to further explore the treatment and prognosis of this technology in the early treatment of sepsis.

Eligibility criteria:
inclusion criteria: * age of 29d to 18 years old; * children diagnosed with sepsis requiring blood purification. exclusion criteria: * with a history of a duration of picu stay \<24 h * active bleeding, including cerebral hemorrhage

Keywords: continuous renal replacement therapy sepsis timing
accuracy, feasibility and acceptance of cgm lupus

Conditions: Systemic Lupus Erythematosus; Critical Illness; Diabetic Blood Glucose Monitoring

Summary: this is a prospective monocenter, non-randomised, open-lable single-group intervention diagnostic trial on the accuracy, reliability and feasibility of the continuous glucose monitoring system in critically systemic lupus erythematosus (sle). newly developed technologies for continuous glucose monitoring in critically sle patients may improve glycemic control and reduce glucose variability. critically sle patients will be performed by continuous glucose monitoring. the subcutaneous glucose will be continuously monitored in critical sle patients by freestyle libre glucose monitoring system for 14 days. the aim of this study is to evaluate accuracy feasibility and acceptance of these methods. to analyze accuracy sensor glucose levels will be validated due to venous blood measurements with glucose oxidase methods. the influence of several factors like oedema, perspiration, bmi, body temperature, ph-value application of vasoconstrictors on accuracy and feasibility of the particular system would be evaluated. furthermore the acceptance of physicians and nursing staff would be evaluated by a questionnaire.


Eligibility criteria:
inclusion criteria: * systemic lupus erythematosus (sle), as defined by meeting at least 4 of 11 classification criteria of american college of rheumatology for the classification of systemic lupus erythematosus, either sequentially or coincidentally. the 4 criteria doesn't need to be present at the time of study enrollment; * critically sle patients * informed consent by the patients or legal proxy exclusion criteria: * age \< 18 * no informed consent by the patients or legal proxy * pregnancy * infaust prognosis

Keywords: glucose systemic lupus erythematosus
eus-guided response assessment to nsbb

Conditions: Portal Hypertension Related to Cirrhosis

Summary: the goal of this clinical trial is to learn if endoscopic ultrasound (eus)-guided portal pressure measurement can determine the treatment response to non-selective beta-blockers (nsbb) in patients with cirrhosis and clinically significant portal hypertension (csph). participants will undergo eus-guided portal pressure measurement before start of carvedilol en after three months of treatment. eus-guided measurements will be paired with transjugular hepatic venous pressure gradient (hvpg) measurement as well as non-invasive tests for assessment of portal hypertension.


Eligibility criteria:
inclusion criteria: * patients with a clinical and/or pathological diagnosis of compensated cirrhosis. * patients with suspicion of csph and thus indication for nsbb treatment. * patients not yet on nsbb therapy. * patients willing and able to undergo repeated hvpg and eus-guided pressure measurements as per protocol. exclusion criteria: general criteria * patient is \ 80 years of age * patient is pregnant, breast-feeding or planning to become pregnant during the course of the study * patient is unwilling or unable to sign the informed consent * patients in whom general anesthesia or endoscopic procedures are contraindicated medical criteria * patients with cirrhosis and hcc portopulmonary hypertension portal or splanchnic venous thrombosis prior tips prior liver transplantation * non-cirrhotic portal hypertension or pre-sinusoidal liver disease * cholestatic liver disease with total bilirubin \>3 mg/dl * previous total or partial splenectomy * known infection that is not controlled by medical intervention * patients with contraindications for non-selective beta-blocker therapy, including but not limited to the following baseline vital signs: systolic bp \<100 mmhg hr \<50 bpm * patients with reduced life expectancy described by an asa score of 4 or 5 * inr \>1.7 or platelet count \<50.000 per mm3 * egfr \<50 ml/min/1.73m2 (ckd-epi formula) anatomical criteria * anatomical abnormalities that prevent access via eus-guided puncture to the hepatic vein or intrahepatic portion of the portal vein, including anatomy that predisposes to difficult to reach puncture sites or an inadequate needle angle. * visualization of ascites interposing the puncture tract on eus * diagnosis of portal vein thrombosis during eus * evidence of active gastrointestinal bleeding during eus

Keywords: portal hypertension eus-ppg hvpg cirrhosis non-selective beta blockers